Allergan: Free-speech suit unrelated to probe

Allergan (AGN) told investors that the suit it filed against the FDA to allow it more freedom to discuss off-label uses of Botox has nothing to do with a Department of Justice probe that has cost the company $7.4 million. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.